(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-12,13-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione

• ChemBase编号: 72742
• 分子式: C38H69NO13
• 平均质量: 747.95336
• 单一同位素质量: 747.47689127
• SMILES: [C@@]1([C@H](OC(=O)[C@@H]([C@H]([C@@H]([C@H]([C@@](C[C@H](C(=O)[C@@H]([C@H]1O)C)C)(OC)C)O[C@@H]1O[C@@H](C[C@@H]([C@H]1O)N(C)C)C)C)O[C@@H]1O[C@H]([C@@H]([C@](C1)(C)OC)O)C)C)CC)(O)C
• Canonical SMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@H]([C@@H](O2)C)O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C[C@H](C(=O)[C@@H]([C@H]([C@]1(C)O)O)C)C)(C)OC
• InChI: InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
• InChIKey: AGOYDEPGAOXOCK-KCBOHYOISA-N

名称和登记号

名称

• IUPAC标准名: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-12,13-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
• IUPAC传统名: clarithromycin; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-12,13-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
• 别名: 6-O-Methylerythromycin; 6-O-Methylerythromycin A; A 56268; Abbott 56268; Antibiotic A 56268; Antibiotic TE 31; BIAXIN XL; Biaxin; CRIXAN OD; Clamicin; Claric; Claris; Claritek; Clarith; Clarithro; Clarithromycin; Clathromycin; Fascar; Kelamycin; Klacid; Klaribac; Klarithran MR; Macladin; Naxy; TE 031; Veclam; Zeclar; Crixan; Klaricid; Klabax; Claripen; Clarem; Claridar; Fromilid; Clacid; Clacee; Vikrol; Infex; Clari; Clarithromycin; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-12,13-dihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetra hydro-2H-pyran-2-yl)oxy)-7-methoxy-3,5,7,9,11,13-hexame thyloxacyclotetradecane-2,10-dione; Cyllind; Mavid;Naxy; Clarithromycin

登记号

• CAS号: 81103-11-9
• PubChem SID: 162037663
• PubChem CID: 84029

理论计算性质

• Acid pKa: 12.458389
• 质子受体: 13
• 质子供体: 4
• LogD (pH = 5.5): 0.4510266
• LogD (pH = 7.4): 2.2163913
• Log P: 3.2395153
• 摩尔折射率: 190.7883 cm^3
• 极化性: 77.6621 Å^3
• 极化表面积: 182.91 Å^2
• 可自由旋转的化学键: 8
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: Chloroform; Ethanol; Methanol
• 外观: White Solid
• 熔点: 217-220°C (dec.)

安全信息

• 保存条件: -20°C; -20°C Freezer

药理学性质

• 作用靶点: DNA/RNA
• 生物活性机理: Inhibitor of the translation of bacterial peptides

产品相关信息

• 成盐信息: Free Base
• 应用领域: Antibacterial agent; Shows superior pharmacokinetic props. to erythromycin and about twice the activity, with a similar spectrum of activity

详细说明

Selleck Chemicals - S2555

Research Area: Cancer
Biological Activity:
Clarithromycin (Biaxin, Klacid) is a macrolide antibiotic and a CYP3A4 substrate and inhibitor. Clarithromycin (Biaxin, Klacid) prevents bacteria from growing by interfering with their protein synthesis. Clarithromycin (Biaxin, Klacid) binds to the subunit 50S of the bacterial ribosome and thus inhibits the translation of peptides. Clarithromycin (Biaxin, Klacid) has similar antimicrobial spectrum as erythromycin but is more effective against certain gram-negative bacteria, particularly Legionella pneumophila. Clarithromycin (Biaxin, Klacid) is used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydia pneumoniae or TWAR), skin and skin structure infections. Besides, clarithromycin (Biaxin, Klacid)is a substrate and inhibitor of CYP3A4. Inhibitors of CYP3A4 may increase clarithromycin (Biaxin, Klacid) serum concentrations. Inducers of CYP3A4 substrates may decrease clarithromycin (Biaxin, Klacid) serum concentrations. [1][2]

Toronto Research Chemicals - C559750

Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is a derivative of Erythromycin (E650000).

参考文献

• Niemi M et al. Clin Pharmacol Ther. 2001 Jul; 70(1):58-65.
• Benson, C., et al.: Eur. J. Clin. Microbiol., 6, 173 (1987)
• Boyanova, L., et al.: J. Med. Microb., 61, 85 (1987)
• Lin, Z., et al.: Toxicol. Sci., 126, 114 (1987)
• Gates, P.J. et al., Rapid Commun. Mass Spectrom., 1999, 13, 242-246, (ms)
• Awan, A. et al., J.C.S. Perkin 2, 2000, 1645-1652, (Erythromycin A, Clarithromycin, pmr, conformn)
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, EDH500; EDJ000; EDI500; EDJ500
• Gasc, J.-C. et al., J. Antibiot., 1991, 44, 313, (synth, pmr, activity)
• Barber, J. et al., J.C.S. Perkin 2, 1991, 1489, (pmr, cmr, tautom, conformn)
• Kirk-Othmer Encycl. Chem. Technol., 4th edn., Wiley, 1991, 3, 171, (rev)
• Weber, J.M. et al., Science (Washington, D.C.), 1991, 252, 114-117, (6-Deoxyerythromycins)
• Toshima, K. et al., Tet. Lett., 1991, 32, 6155, (synth)
• Sturgill, M.G. et al., Ann. Pharmacother., 1992, 26, 1099, (rev)
• Piscitelli, S.C. et al., Clin. Pharm., 1992, 11, 137, (Clarithromycin, rev)
• Peters, D.H. et al., Drugs, 1992, 44, 117, (Clarithromycin)
• Iwasaki, H. et al., Acta Cryst. C, 1993, 49, 1227, (cryst struct, Clarithromycin)
• Fraschiui, F. et al., Clin. Pharmacokinet., 1993, 25, 189, (Clarithromycin, rev)
• Watanabe, Y. et al., J. Antibiot., 1993, 46, 1163, (Clarithromycin)
• Pat. Coop. Treaty (WIPO), 1993, 93 13 663; CA, 119, 219166t, (derivs)
• Donadio, S. et al., Proc. Natl. Acad. Sci. U.S.A., 1993, 90, 7119-7123, (6,7-Anhydroerythromycin C)
• Kirst, H.A., Prog. Med. Chem., 1993, 30, 57, (rev)
• Shida, Y. et al., Tetrahedron, 1993, 49, 9221, (ms)
• Negwer, M., Organic-Chemical Drugs and their Synonyms, 7th edn., Akademie-Verlag, 1994, 11577; 11628; 11659; 11757
• Langtry, H.D. et al., Drugs, 1997, 53, 973-1004, (rev, Clarithromycin)
• Martin, S.F. et al., J.A.C.S., 1997, 119, 3193, (synth)
• Tyson, P. et al., J. Chem. Res., Synop., 1998, 727, (pmr, cmr)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 189
• Clark, R.K. et al., Antibiot. Chemother. (Washington, D.C.), 1955, 5, 206, (struct)
• Wiley, P.F. et al., J.A.C.S., 1955, 77, 3422; 1957, 79, 6062; 6074, (struct)
• Oleinick, N.L., Antibiotics (N.Y.), 1975, 3, 396, (rev)
• Terui, Y. et al., Tet. Lett., 1975, 2583, (cmr)
• Majer, J. et al., J.A.C.S., 1977, 99, 1620, (pmr)
• Tadanier, J. et al., J.O.C., 1978, 43, 2351, (synth)
• Koch, W.L. et al., Anal. Profiles Drug Subst., 1979, 8, 159, (rev)
• Gribble, M.J. et al., Med. Clin. North Am., 1982, 66, 79, (rev, pharmacol)
• Morimoto, S. et al., J. Antibiot., 1984, 37, 187, (Clarithromycin)
• Belg. Pat., 1985, 901 411; CA, 104, 19776
• Washington, J.A. et al., Mayo Clin. Proc., 1985, 60, 189, (rev, pharmacol, metab)
• Paterson, I. et al., Tetrahedron, 1985, 41, 3569, (synth, rev)
• Fernandes, P.B. et al., Antimicrob. Agents Chemother., 1986, 30, 865; 1987, 31, 328; 343; 463; 640, (Clarithromycin)
• Chater, K.F., Bacteria, 1986, 9, 119, (rev, biosynth)
• Concia, P.M. et al., J. Int. Med. Res., 1986, 14, 137, (RV11)
• Cane, D.E. et al., J.A.C.S., 1986, 108, 4957, (biosynth)
• Everett, J.R. et al., J.C.S. Perkin 2, 1987, 1659; 1988, 325; 1989, 1719, (pmr, cmr, conformn, cryst struct)
• Ager, D.J. et al., Magn. Reson. Chem., 1987, 25, 948, (cmr)
• Lewis, R.J., Food Additives Handbook, Van Nostrand Reinhold International, New York, 1989, EDH500
• Watanabe, Y. et al., Heterocycles, 1990, 31, 2121, (Clarithromycin)
• Hunt, E. et al., J.C.S. Perkin 2, 1990, 2157, (synth, ir, pmr)
• Stanton, J., Angew. Chem., Int. Ed., 1991, 30, 1302, (rev, biosynth)
• Muelzer, J., Angew. Chem., Int. Ed., 1991, 30, 1452, (rev, synth)
• Shepherd, M.J., Food Contaminants: Sources and Surveillance, Royal Society of Chemistry, 1991, 145, (anal)